Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has entered into a collaboration and license agreement with biotech company Alvotech to codevelop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, according to a Wednesday filing to the Indian stock exchanges.
Keytruda is used to treat a number of cancer types.
Under the pact, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. The parties will have the right to commercialize the product globally.
In 2024, worldwide sales of Keytruda were estimated at $29.5 billion.
The company's shares were up nearly 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.